

11/06/2020

**Healthcare Professional Communication**

**Product Name: Belvo 250 mg gastro-resistant tablets**

**Product Licence Number: PL 24837/0108**

Dear Healthcare Professional,


Consilient Health would like to inform you that a batch specific request has been approved by the MHRA for two of our batches of Belvo 250 mg gastro-resistant tablets (batch number 19FQ052 and 19FQ053).

These batches previously had an expiry date of June 2020 however with the support of stability data the shelf life has been extended to the end of December 2020. This change was reviewed and subsequently approved by the MHRA in June 2020.

The blister and carton packed for sale have been updated to reflect this extension and therefore we do not anticipate any concerns from the patients however please do not hesitate to contact us if you do receive any comments or queries. Details of the MHRA Yellow Card Scheme are also provided below for your information.

Please ensure that this letter is provided to both your Superintendent Pharmacist and also your local Pharmacists within your organisation.

Yours sincerely,



Mark Ireland

UK Country Manager – Generic Pharmaceuticals and Trade Management.  
m +44 (0)7795 553943

**MHRA Call for reporting**

Healthcare professionals are asked to report any suspected adverse reactions to the Yellow Card Scheme electronically. Report via the website <https://www.gov.uk/yellowcard>, the free Yellow Card app available from the Apple App Store or Google Play Store, and some clinical IT systems (EMIS, SystemOne, Vision, MiDatabank) for healthcare professionals. Suspected side effect can also be reported by calling 0800 731 6789 for free.

*Date of preparation: June 2020*  
*Job bag no. CORP-GEN-30*